Company profile: Vortex Biosciences
1.1 - Company Overview
Company description
- Provider of oncology diagnostics integrating cancer biology, microfluidic engineering, and informatics to isolate and characterize circulating tumor cells (CTCs). Offers the VTX-1 Liquid Biopsy System for label-free isolation of viable CTCs from blood, CTC enrichment using disposable cartridges, CTC analysis and downstream assays, and cell handling in formats compatible with different workflows.
Products and services
- CTC Analysis & Downstream Assays: Architects assay-based analysis of isolated CTCs using immunofluorescence, cell staining, cytogenetics, and genomics to characterize cells in oncology research
- CTC Enrichment: Constructs disposable cartridge-based enrichment that isolates CTCs from liquid biopsy samples without sample preparation, supplying viable cells suitable for downstream analysis workflows
- VTX-1 Liquid Biopsy System: Engineers a label-free instrument that automates isolation and collection of viable circulating tumor cells directly from blood samples for cancer research
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vortex Biosciences
Circle Pharma
HQ: United States
Website
- Description: Provider of bioavailable macrocyclic peptide therapeutics targeting intracellular protein-protein interactions, supported by the MXMO platform that combines computational structure-based design and synthetic chemistry to create cell-permeable macrocycles. Offers cyclin A/B inhibitors for cancers with Retinoblastoma pathway mutations and other tumors, advancing precision oncology and therapeutics for 'undruggable' targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Circle Pharma company profile →
Blaze Bioscience
HQ: United States
Website
- Description: Provider of products that assist surgeons treating cancer patients, including BLZ-100 (tozuleristide), a fluorescent imaging agent used in brain cancer surgery to help visualize tumors, and the CANVAS Imaging System, used in conjunction with BLZ-100 to detect and visualize tumors during surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blaze Bioscience company profile →
Advanced Accelerator Applications
HQ: France
Website
- Description: Provider of targeted radioligand therapies and precision imaging radioligands, offering LUTATHERA: a radioligand therapy using lutetium Lu 177 dotatate for treating tumors; PLUVICTO: a therapeutic radioligand containing lutetium Lu 177 vipivotide tetraxetan; diagnostic PET imaging kits NETSPOT, LOCAMETZ, and SOMAKIT TOC; and LysaKare to reduce renal radiation exposure during peptide-receptor radionuclide therapy with LUTATHERA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Accelerator Applications company profile →
Amphivena Therapeutics
HQ: United States
Website
- Description: Provider of a platform of dual-function biologics in clinical-stage immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amphivena Therapeutics company profile →
Sorrento Therapeutics
HQ: United States
Website
- Description: Provider of proprietary drug therapeutics under development to address unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sorrento Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vortex Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vortex Biosciences
2.2 - Growth funds investing in similar companies to Vortex Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vortex Biosciences
4.2 - Public trading comparable groups for Vortex Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →